Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Lamotrigine

An antiepileptic of the phenyltriazine family, in use since the early 1990s and approved in the United States in 1994; since 2003 it has also been indicated to prevent depressive episodes in bipolar disorder. This family brings together the active ingredient, pharmacopoeial impurities, metabolites, labelled standards and other impurities.

Did you know?It was born from a wrong hypothesis: an antiepileptic was thought to need to lower folic acid. While searching for antifolates, researchers found that some phenyltriazines, weak on folate, were potent anticonvulsants.

LamotrigineGo to the active ingredient →
LamotrigineActive ingredientLamotrigineCat. No. P-L010-001CAS 84057-84-1

EDQM standards 4

The official European Pharmacopoeia standards for this family.

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.